Unlike many drug classes, GLP-1 receptor agonists are peptides metabolized primarily through proteolytic degradation rather than the cytochrome P450 liver enzyme system that drives most classic drug-drug interactions. This means semaglutide and tirzepatide don't compete with other medications for the same metabolic pathways the way, for example, many psychiatric or cardiovascular drugs do with each other. That doesn't mean interaction risk is zero — it means the risk operates through a different, mechanical mechanism.
The primary interaction mechanism: delayed gastric emptying
GLP-1 receptor agonists slow gastric emptying as part of their core mechanism of action — the same effect that contributes to appetite suppression also delays how quickly other oral medications move through the stomach and into the small intestine, where most drug absorption occurs.[1] For most medications, this delay doesn't meaningfully change how much drug ultimately gets absorbed, only how quickly — a difference that rarely matters clinically. For a specific subset of drugs, the timing shift is more consequential.
Documented interaction categories
Oral contraceptives
Delayed gastric emptying is a documented consideration for oral contraceptives specifically, since consistent, predictable absorption timing matters for contraceptive efficacy. Product labeling for GLP-1 medications has addressed this consideration, generally without establishing a definitive clinically significant efficacy reduction in steady-state dosing, but it remains a documented interaction category prescribers are advised to discuss with patients.
Insulin and insulin secretagogues (sulfonylureas)
This is the most clinically significant and well-established interaction category. GLP-1 receptor agonists lower blood glucose partly by stimulating glucose-dependent insulin secretion; when combined with insulin or sulfonylureas — which stimulate insulin release independent of blood glucose level — the combined effect can produce hypoglycemia. This is a well-documented interaction requiring dose adjustment (typically a reduction in insulin or sulfonylurea dose) when GLP-1 therapy is initiated in patients already on these medications.[2]
Warfarin
No direct pharmacokinetic interaction between GLP-1 receptor agonists and warfarin has been firmly established, but changes in appetite, food intake, and resulting vitamin K consumption during GLP-1-driven weight loss can indirectly affect INR (international normalized ratio) stability in patients on warfarin — a reason for closer INR monitoring during dose titration rather than a direct drug-drug interaction in the pharmacological sense.
Oral levothyroxine
Similar to oral contraceptives, delayed gastric emptying is a documented consideration for oral levothyroxine absorption timing, relevant for patients on thyroid hormone replacement starting GLP-1 therapy — again generally addressed through monitoring (periodic TSH checks) rather than an absolute contraindication.
Tirzepatide-specific considerations
As a dual GIP/GLP-1 receptor agonist, tirzepatide carries the same gastric-emptying-mediated interaction profile as GLP-1-only agents, with FDA labeling specifically flagging oral hormonal contraceptives as warranting counseling about a temporary barrier method or adjusted timing, particularly during initial dose escalation when gastric emptying effects are typically most pronounced.[3]
Why the interaction risk is highest during titration
Gastric emptying delay is generally most pronounced during initial dosing and dose escalation, and tends to attenuate somewhat with continued use as the body adapts — meaning interaction risk isn't necessarily constant throughout treatment. This is part of the clinical rationale for closer monitoring specifically around dose changes, rather than only at treatment initiation.
What's not well-characterized in the literature
Interactions with the growing category of oral small-molecule GLP-1s in development (elecoglipron, orforglipron) have a much thinner post-marketing evidence base than injectable agents, given their more recent approval and ongoing Phase 3 development — prescribers and patients should expect this literature to expand as real-world use accumulates.
Interaction data specific to compounded formulations — different salt forms, delivery vehicles, or combination products — is essentially absent from the peer-reviewed literature, since these products haven't undergone the same premarket interaction studies FDA-approved formulations require.
The practical takeaway
The interaction profile of GLP-1 receptor agonists is narrower and more mechanistically predictable than many other widely prescribed drug classes — there is no large, unpredictable web of CYP450-mediated interactions to screen for. The known interaction categories are specific, documented, and generally managed through monitoring and dose adjustment rather than avoidance, which is why comprehensive medication disclosure to every prescriber remains the single most effective interaction-prevention step available to patients.
Compare GLP-1 telehealth providers
Source GLP-1 tracks pricing, licensing, and provider structure across the market.